Mari Edlin

The opioid epidemic is far from over, but it may slip behind other challenges. COVID-19 obviously tops the list of new problems and drug pricing and affordability will continue to soak up time and attention.

They are waiving cost sharing for COVID-19 treatment. How large will premium increases be next year?

New point-of-care tools offer greater transparency.

Payers are finding ways for members to afford expensive specialty drug treatments.

Authorized generics have been gaining popularity with pharmaceutical manufacturers, but just how do they impact pharmacies?

Drug shortages might be decreasing, but their continued existence is urging the pharmacy industry to maintain its vigilance.

Opportunities to lower drug prices, as promised by President Trump’s American Patients First Blueprint, are picking up steam, some progressing more quickly than others.

CMS introduced indication-based formularies as a voluntary tool for plans to implement in 2020.

The real-world strategies used to manage the high cost of specialty meds.

The Trump Administration has taken a large interest in PBM drug rebates, which they say create higher drug prices. But do they?

The stakes have never been higher in reducing readmissions and hospitals are leveraging pharmacists’ expertise and putting them at the forefront of readmission reduction programs

The biggest drug categories and medications set for approval this year.

What experts say will be the year’s biggest problems, and what can be done about them.

These products aid in treating several conditions, but are insurers paying for them? Find out.

Innovative PBM performance-based pharmacy networks focus on reducing costs and Improving clinical outcomes

In response to the lack of transparency, health organizations are creating drug pricing tools that deliver patient-specific pricing. Here’s how they work.

Prices of more than 20% of generic drugs increased more than 100% between 2010 and 2015.

Legislation removes FDA involvement when patients seek experimental medications. Here’s what critics and proponents say.

A panel at AMCP's annual meeting discussed the need to improve MS medication adherence.

The P&T committee is positioned to provide knowledge, strategies to improve treatment of patients with cardiometabolic disorders.